These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23745738)

  • 21. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calbindin Deficits May Underlie Dissociable Effects of 5-HT
    Shortall SE; Brown AM; Newton-Mann E; Dawe-Lane E; Evans C; Fowler M; King MV
    Mol Neurobiol; 2020 Aug; 57(8):3439-3457. PubMed ID: 32533466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential role of lamotrigine in schizophrenia.
    Large CH; Webster EL; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice.
    Horio M; Fujita Y; Hashimoto K
    Fundam Clin Pharmacol; 2013 Oct; 27(5):483-8. PubMed ID: 22594375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
    Stansley BJ; Conn PJ
    Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.
    Olszewski RT; Wegorzewska MM; Monteiro AC; Krolikowski KA; Zhou J; Kozikowski AP; Long K; Mastropaolo J; Deutsch SI; Neale JH
    Biol Psychiatry; 2008 Jan; 63(1):86-91. PubMed ID: 17597589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia clues from monkeys.
    Pennisi E
    Science; 1997 Aug; 277(5328):900. PubMed ID: 9281070
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE; Schaffhauser H; Campbell UC
    Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verbal memory.
    Sumiyoshi T
    Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical findings with new antipsychotic agents: what makes them atypical?
    Jackson DM; Ryan C; Evenden J; Mohell N
    Acta Psychiatr Scand Suppl; 1994; 380():41-8. PubMed ID: 7914047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
    Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
    Elife; 2018 Oct; 7():. PubMed ID: 30355445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
    Uzuneser TC; Schindehütte M; Dere E; von Hörsten S; Kornhuber J; Grömer TW; Müller CP
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1382-1393. PubMed ID: 30243682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models.
    Shah UH; González-Maeso J
    ACS Chem Neurosci; 2019 Jul; 10(7):3068-3077. PubMed ID: 30807107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a serotonin/glutamate receptor complex implicated in psychosis.
    González-Maeso J; Ang RL; Yuen T; Chan P; Weisstaub NV; López-Giménez JF; Zhou M; Okawa Y; Callado LF; Milligan G; Gingrich JA; Filizola M; Meana JJ; Sealfon SC
    Nature; 2008 Mar; 452(7183):93-7. PubMed ID: 18297054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs.
    Cochran SM; Kennedy M; McKerchar CE; Steward LJ; Pratt JA; Morris BJ
    Neuropsychopharmacology; 2003 Feb; 28(2):265-75. PubMed ID: 12589379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
    Walker AG; Conn PJ
    Curr Opin Pharmacol; 2015 Feb; 20():40-5. PubMed ID: 25462291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validating novel targets for pharmacological interventions in schizophrenia.
    Wroblewska B; Lewis DA
    Am J Psychiatry; 2009 Jul; 166(7):753-6. PubMed ID: 19570936
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.